LRRK2 (R1441H), GST-Tag Recombinant

Catalog #

40837

$465 *

Size: 10 µg

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Human LRRK2 protein with a R1441H mutation, also known as PARK8, RIPK7, and ROCO2, GenBank Accession No. NM_198578, amino acids 968-end, with an N-terminal GST-tag, expressed in an SF9cell expression system. MW = 210 kDa.

●

Synonyms

PARK8; RIPK7; ROCO2; AURA17; DARDARIN

●

Product Data Gallery

Product Info

Storage and Usage

Citations

Species

Human

Host Species/Expression System

Sf9 insect cells

Formulation

50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, 25% glycerol.

210 kDa

Amino Acids

968-end

Specific Activity

≥ 21 pmol/min/µg

Genbank #

NM_198578

UniProt #

Q5S007

Tag(s)

N-terminal GST tag

Background

LRRK2 or leucine-rich repeat kinase is a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. Mutations in LRRK2 are the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease with prevalent mutations being found within the GTPase and kinase domains (1). LRRK2 cooperates with MET to promote efficient tumor cell growth and survival in various cancers. Down-regulation of LRRK2 in cultured tumor cells compromises MET activation and selectively reduces downstream MET signaling to mTOR and STAT3 (2).

LRRK2 (R1441H), GST-Tag Recombinant

PRODUCTS

SERVICES

RESOURCES

COMPANY